Namee Kim, MD
Cardiovascular Disease · San Diego, CANPI 1164745725
Payments from drug & device makers
Across 282 payments — averaging $21.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$877
- Novartis$628
- Johnson & Johnson$518
- Boston Scientific$492
- Pfizer$475
- E.r. Squibb & Sons, L.L.C.$441
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,152100%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 10 | $877 |
| Novartis | 35 | $628 |
| Johnson & Johnson | 36 | $518 |
| Boston Scientific | 24 | $492 |
| Pfizer | 26 | $475 |
| E.r. Squibb & Sons, L.L.C. | 37 | $441 |
| Amgen | 13 | $267 |
| Philips North America LLC | 4 | $249 |
| Braemar Manufacturing, LLC | 1 | $234 |
| Abbott | 10 | $226 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $225 |
| AstraZeneca | 9 | $151 |
| Lantheus Medical Imaging, Inc. | 7 | $150 |
| Cvrx, Inc. | 9 | $142 |
| Sanofi-aventis U.S. LLC | 7 | $130 |
| Biotronik Inc. | 2 | $127 |
| Boehringer Ingelheim | 4 | $102 |
| Esperion Therapeutics, Inc. | 6 | $98 |
| Alnylam Pharmaceuticals Inc. | 4 | $79 |
| Amarin Pharma, Inc. | 3 | $69 |
| Irhythm Technologies, Inc. | 4 | $65 |
| Novo Nordisk | 3 | $62 |
| Kiniksa Pharmaceuticals, Ltd. | 3 | $59 |
| Regeneron Healthcare Solutions, Inc. | 2 | $38 |
| Baxter Healthcare | 2 | $35 |
| Astellas Pharma US Inc | 2 | $35 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $33 |
| Medicomp Inc | 2 | $32 |
| Kestra Medical Technology Services, Inc. | 1 | $28 |
| Gilead | 1 | $24 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| Merck | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LINQ II$442
- Cardiac Monitoring Suite$234
- (7999) SRC Undivided$188
- Reveal LINQ$153
- LifeVest$101
How this compares
$6,170 in reported general payments places this provider in the 65th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 564 | $731,714 |
| XareltoRivaroxaban | 169 | $222,409 |
| Repatha SureclickEvolocumab | 105 | $127,159 |
| MultaqDronedarone Hcl | 50 | $103,988 |
| EntrestoSacubitril/Valsartan | 44 | $63,920 |
| Praluent PenAlirocumab | 59 | $58,028 |
| JardianceEmpagliflozin | 21 | $25,641 |
| Rosuvastatin Calcium | 1,151 | $16,615 |
| FarxigaDapagliflozin Propanediol | 12 | $15,762 |
| BrilintaTicagrelor | 16 | $12,294 |
| Metoprolol Succinate | 571 | $10,067 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 183 | $5,794 |
| Ezetimibe | 141 | $5,577 |
| Losartan Potassium | 524 | $5,488 |
| Atorvastatin Calcium | 533 | $5,474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $475 | $731,714564 claims |
| Johnson & JohnsonXarelto | $518 | $222,409169 claims |
| Sanofi-aventis U.S. LLCMultaq | $130 | $103,98850 claims |
| NovartisEntresto | $628 | $63,92044 claims |
| AstraZenecaFarxiga, Brilinta | $151 | $28,05728 claims |
| Boehringer IngelheimJardiance | $102 | $25,64121 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in San Diego
- Lori DanielsSan Diego$10.2M
- Michael WilkinsonSan Diego$1.9M
- William PennySan Diego$829K
- Ajit RaisinghaniSan Diego$695K
- Kevin KingSan Diego$598K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
- Paul KurthSanta Barbara$6.1M
- Michael BlumSan Francisco$5.5M
- Tony ChouSan Francisco$5.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.